SCHEMBL4079782

SCHEMBL4079782

Cc1cc(C)c2[nH]c(=O)c(CN(Cc3ccc4c(c3)OCO4)C(=O)NC3CC3)cc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.56
ALDH1A1 P00352 8/20 0.56
HSD17B10 Q99714 7/20 0.56
TSHR P16473 4/20 0.56
ALOX15 P16050 3/20 0.56
NPSR1 Q6W5P4 3/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
HTT P42858 2/20 0.56
CASP1 P29466 1/20 0.56
MAPT P10636 3/20 0.56
HPGD P15428 3/20 0.56
LMNA P02545 3/20 0.56
MAPK1 P28482 1/20 0.56
POLB P06746 2/20 0.55
USP2 O75604 1/20 0.55
GUSB P08236 3/20 0.53
GAA P10253 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
PKM P14618 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4080208 0.88 KDM4E (0.56) KDM4EALDH1A1HSD17B10TSHRALOX15
SCHEMBL4070133 0.87 KDM4E (0.55) KDM4EALDH1A1HSD17B10TSHRALOX15
SCHEMBL5463453 0.87 KDM4E (0.59) KDM4EALDH1A1HSD17B10TSHRALOX15
SCHEMBL4073864 0.86 KDM4E (0.55) KDM4EALDH1A1HSD17B10TSHRALOX15
SCHEMBL5457669 0.85 KDM4E (0.65) KDM4EALDH1A1HSD17B10TSHRALOX15
SCHEMBL4077969 0.85 KDM4E (0.61) KDM4EALDH1A1HSD17B10TSHRALOX15
SCHEMBL5448947 0.85 KDM4E (0.66) KDM4EALDH1A1HSD17B10TSHRALOX15
SCHEMBL4073672 0.85 ALDH1A1 (0.58) KDM4EALDH1A1HSD17B10TSHRALOX15
SCHEMBL4079794 0.85 ALDH1A1 (0.53) KDM4EALDH1A1HSD17B10TSHRALOX15
SCHEMBL4077438 0.85 KDM4E (0.54) KDM4EALDH1A1HSD17B10TSHRALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof AGRIUS GROUP, LLC. 2007-12-13 US claimed
EP-2040711-A2 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS Amphora Discovery Corporation (US) 2009-04-01 EP disclosed
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof AGRIUS GROUP, LLC. 2007-12-13 US disclosed
WO-2007136592-A2 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS AMPHORA DISCOVERY CORPORATION (US) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287706-A1 Certain substituted quinolones, compositions, and uses thereof ABCG2, ATP5ME, ATP5MG KDM4E 2403/4885ALDH1A1 1055/4885HSD17B10 1580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.